Home/Tag: Pfizer

Global GIST Advocates Convene at LRG Headquarters

The Life Raft Group had the pleasure of hosting the global New Horizons GIST meeting this year in our Wayne, New Jersey office. This international meeting traditionally gathers global GIST advocates with the shared [...]

By |2019-09-24T11:24:53-04:00December 28th, 2017|Advocacy, Global, News, Newsletter|

La Jolla Provided a Beautiful Backdrop for Our Three-Day July Event

The Life Raft Group and UCSD hosted a three-day event at University of California, San Diego UCSD-Moores Cancer Center from July 13th through July 15th. A GIST Awareness Day (GAD) event took place on July [...]

By |2019-08-01T10:07:21-04:00September 18th, 2017|Advocacy, Caregiver Support, Events, GDOL, GIST Education, News, Newsletter|

Stivarga becomes first FDA-approved third-line drug treatment for GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.

By |2019-09-20T12:49:52-04:00April 1st, 2013|Drug Treatment, News, Side Effects, Stivarga|

Pfizer to open clinical trial for young patients with GIST

A new phase I/II clinical trial will soon be opening for pediatric and young adults with GIST. This trial will be testing Sutent (sunitinib), the currently approved second-line treatment for GIST, in young patients. At the current time, the optimal dose for Sutent is not known for pediatric patients. This trial will help assess the safety and tolerability of Sutent in young patients.

By |2019-09-20T16:17:06-04:00December 1st, 2011|Clinical Trials, News, Pediatric GIST|
Go to Top